I. King

发表

Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides.

Y. Cheng, T. Doyle, E. Gullen, 1998, Bioorganic & medicinal chemistry letters.

Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models.

X. Luo, D. Bermudes, T. Le, 2001, Oncology research.

Use of preferentially replicating bacteria for the treatment of cancer.

M. Sznol, D. Bermudes, S. Lin, 2000, The Journal of clinical investigation.

Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

X. Luo, Z. Li, J. Pawelek, 2000, The Journal of infectious diseases.

Antiviral Activity of β-l-2′,3′-Dideoxy-2′,3′-Didehydro-5-Fluorocytidine in Woodchucks Chronically Infected with Woodchuck Hepatitis Virus

M. Chevallier, F. Zoulim, S. Guerret, 2001, Antimicrobial Agents and Chemotherapy.

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.

M. Andreeff, M. Sznol, G. Garcia-Manero, 2006, Leukemia research.

Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent.

M. Belcourt, D. Bermudes, Stanley L. Lin, 2002, Human gene therapy.

Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation

M. Sznol, R. Dubielzig, D. Thamm, 2005, Clinical Cancer Research.

Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector.

X. Luo, D. Bermudes, T. Le, 2001, Oncology research.

Construction of VNP20009

J. Pawelek, K. B. Low, D. Bermudes, 2004 .

Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans.

J. Pawelek, K. B. Low, D. Bermudes, 2004, Methods in molecular medicine.

Characterization of the Antiviral Effect of 2′,3′-Dideoxy-2′, 3′-Didehydro-β-l-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model

Yung-chi Cheng, M. Chevallier, F. Zoulim, 2000, Antimicrobial Agents and Chemotherapy.

Synthesis and biological evaluation of a water soluble phosphate prodrug of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP).

T. Doyle, S. Chen, Q. Wang, 1998, Bioorganic & medicinal chemistry letters.

Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.

T. Doyle, I. King, L. Zheng, 2001, Current medicinal chemistry.

Case Study: Identification of in vitro Metabolite/Decomposition Products of the Novel DNA Alkylating Agent Laromustine

A. Nassar, M. Belcourt, T. Lam, 2010 .

Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism

E. Maxwell, J. Catino, D. Ojcius, 1996, The Journal of experimental medicine.

Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models

I. King, Zujin Li, Li-mou Zheng, 2007, Cancer Chemotherapy and Pharmacology.

Tumour therapy using Salmonella

M. Sznol, X. Luo, M. Belcourt, 2000 .

Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy.

D. Bermudes, I. King, Martina Itterson, 2009, Methods in molecular biology.

Tumour-Selective Salmonella-Based Cancer Therapy

M. Belcourt, J. Pawelek, K. B. Low, 2001, Biotechnology & genetic engineering reviews.

Characterization of the Antiviral Effect of 2 9 ,3 9 -Dideoxy-2 9 , 3 9 -Didehydro- b - L -5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model

M. Chevallier, F. Zoulim, C. Trépo, 1999 .

Synthesis and comparative evaluation of two antiviral agents: β-l-Fd4C and β-d-Fd4C

T. Doyle, E. Gullen, Stanley L. Lin, 1998 .

Interaction of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: implications for human immunodeficiency virus drug design.

M. Kukhanova, Y. Cheng, W. Prusoff, 1998, Molecular pharmacology.

Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.

T. Doyle, M. Feng, S. Chen, 1998, Bioorganic & medicinal chemistry letters.

Bis‐S‐acyl‐2‐thioethyl (SATE)‐Bearing Monophosphate Prodrug of β‐L‐FD4C as Potent anti‐HBV Agent.

T. Doyle, I. King, X. Li, 1998 .

Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo

Samuel I. Miller, Jessica Fischer, J. Platt, 1999, Nature Biotechnology.

Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy

Panos Lehouritis, Lawrence Davies, Richard Marais, 2008, Clinical Cancer Research.

Live bacteria as anticancer agents and tumor-selective protein delivery vectors.

D. Bermudes, I. King, Li-mou Zheng, 2002, Current opinion in drug discovery & development.

Salmonella-based tumor-targeted cancer therapy: tumor amplified protein expression therapy (TAPET) for diagnostic imaging.

X. Luo, D. Bermudes, I. King, 2001, Journal of controlled release : official journal of the Controlled Release Society.

Case Study: The Unanticipated Loss of N2 from Novel DNA Alkylating Agent Laromustine by Collision‐Induced Dissociation: Novel Rearrangements

A. Nassar, M. Belcourt, T. Lam, 2010 .

Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.

S. Keir, D. Bigner, L. Muhlbaier, 2007, Neuro-oncology.

Comparative Evaluation of the Acute Toxic Effects in Monkeys, Pigs and Mice of a Genetically Engineered Salmonella Strain (VNP20009) Being Developed as an Antitumor Agent

Jessica Fischer, D. Bermudes, C. Clairmont, 2000 .

Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats

A. Nassar, A. Wisnewski, I. King, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain, TAPET-CD, being developed as an antitumor agent.

I. King, L. Zheng, K. C. Lee, 2001, International journal of toxicology.

Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients

A. Nassar, A. Wisnewski, I. King, 2017, Xenobiotica; the fate of foreign compounds in biological systems.

An in Vitro Evaluation of the Victim and Perpetrator Potential of the Anticancer Agent Laromustine (VNP40101M), Based on Reaction Phenotyping and Inhibition and Induction of Cytochrome P450 Enzymes

A. Nassar, A. Parkinson, B. Ogilvie, 2009, Drug Metabolism and Disposition.

Biotransformation and Rearrangement of Laromustine

A. Nassar, A. Wisnewski, I. King, 2016, Drug Metabolism and Disposition.

Title Page Biotransformation and Rearrangement of Laromustine

A. Nassar, A. Wisnewski, I. King, 2016 .

Development and Validation of LC-MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human Plasma.

A. Nassar, A. Wisnewski, Tukiet T. Lam, 2018, Journal of chromatographic science.

Characterization of short-lived electrophilic metabolites of the anticancer agent laromustine (VNP40101M).

J. Du, I. King, A-E. F. Nassar, 2011, Chemical research in toxicology.